Has Roheen Raithatha, MD received payments from drug or device companies?

Yes. Drug and device makers reported $830,456 in general payments to Roheen Raithatha, MD across 1,138 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roheen Raithatha, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roheen Raithatha, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roheen Raithatha, MD

Otolaryngology · New York, NYNPI 1851558936

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $623,388 of the $830,456 with a category attached, or 75.1%. 29 manufacturers reported payments, led by Sanofi at 32.8% of the total. 2025 is the largest year on record at $287,593, 2.8 times the $102,279 reported in 2019. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$830,456in general payments, 2019–2025

Across 1,138 payments — averaging $729.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Sanofi$272K
Medtronic$209K
Regeneron Healthcare Solutions, Inc.$128K
Optinose US, Inc.$92K
Aerin Medical Inc.$43K
Intersect ENT, Inc.$39K
plus $47K from 23 others

$51,734in research payments, 2019–2025

Across 34 payments — averaging $1521.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Stryker$30K
Optinose US, Inc.$15K
Arrinex, Inc.$7K

What the payments were for

Consulting fees$88,60511%
Speaking & faculty fees$623,38875%
Travel & lodging$85,65810%
Food & beverage$32,7784%
Education$280%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Sanofi	292	$272,466
Medtronic(2 entities)	245	$208,681
Regeneron Healthcare Solutions, Inc.	133	$128,389
Optinose US, Inc.	165	$91,939
Aerin Medical Inc.	40	$43,379
Intersect ENT, Inc.	62	$39,062
GSK	63	$29,013
AstraZeneca	23	$8,541
Stryker	43	$3,433
Regeneron	3	$2,478
Neurent Medical Limited	13	$1,329
Kaleo, Inc.	21	$436
Spirair, Inc.	1	$294
Arrinex, Inc.	1	$237
Sanofi-aventis U.S. LLC	5	$186
Alk-abello, Inc	6	$94
Aimmune Therapeutics, Inc.	3	$71
Integra Lifesciences Corporation	2	$59
Smith+Nephew	3	$56
Acclarent, Inc	2	$46
Novartis	2	$41
Hikma Pharmaceuticals USA	2	$40
Amgen	1	$38
Phadia US Inc.	2	$34
Boehringer Ingelheim	1	$33
Takeda Pharmaceuticals U.S.A., Inc.	1	$24
Teva Pharmaceuticals USA, Inc.	1	$23
Merck	1	$21
Octapharma USA, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$444,495
Xhance$90,017
PROPEL$74,873
NUVENT$45,514
VIVAER STYLUS$42,716
NUCALA$27,938
FUSION$24,163
SINUVA$13,247
RHINAER STYLUS$12,764
STEALTHSTATION S8 PLATFORM$11,573
TEZSPIRE$6,763
ALAR$4,773
CLARIFIX$1,287
NEUROMARK Device$1,091
NEUROMARK Radiofrequency Console$879
XPRESS ENT DILATION SYSTEM$744
SeptAlign$588
TURBALIGN$588
SCOPIS ENT$384
ENTELLUS MEDICAL REINFORCED ANESTHESIA NEEDLE$384

How this compares

$830,456 in reported general payments places this provider in the 95th percentile of 701 otolaryngology providers in New York.

See all otolaryngology providers in New York →

Medicare billing

Part B allowed, 2024

$102,266

Medicare patients

120

Services billed

421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Dupixent PenDupilumab	47	$176,886
Dupixent SyringeDupilumab	21	$71,198
Fluticasone Propionate	23	$247
Ipratropium Bromide	11	$165
Doxycycline Hyclate	11	$64

Paid to pharmacies, not to this prescriber.

Other otolaryngology in New York

Dennis KrausNew York$159K
Anthony DelsignoreNew York$89K
Satish GovindarajNew York$39K
Lawrence LustigNew York$33K
Justin GolubNew York$30K
Brett MilesNew York$30K
David HiltzikNew York$25K
Milan AminNew York$23K
Ashutosh KackerNew York$20K
Michael PitmanNew York$17K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →